[go: up one dir, main page]

MX2015000980A - Inhibidores de aril lactama cinasa. - Google Patents

Inhibidores de aril lactama cinasa.

Info

Publication number
MX2015000980A
MX2015000980A MX2015000980A MX2015000980A MX2015000980A MX 2015000980 A MX2015000980 A MX 2015000980A MX 2015000980 A MX2015000980 A MX 2015000980A MX 2015000980 A MX2015000980 A MX 2015000980A MX 2015000980 A MX2015000980 A MX 2015000980A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
aryl lactam
lactam kinase
aryl
compounds
Prior art date
Application number
MX2015000980A
Other languages
English (en)
Inventor
Vivekananda M Vrudhula
Senliang Pan
Ramkumar Rajamani
John E Macor
Joanne J Bronson
Carolyn Diane Dzierba
Susheel Jethanand Nara
Maheswaran Sivasamban Karatholuvhu
Tarun Kumar Maishal
Jonathan L Ditta
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2015000980A publication Critical patent/MX2015000980A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere, en general, a compuestos que pueden inhibir AAK1 (cinasa asociada al adaptador 1), a composiciones que comprenden estos compuestos y a métodos para inhibir AAK1.
MX2015000980A 2012-07-31 2013-07-24 Inhibidores de aril lactama cinasa. MX2015000980A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261677856P 2012-07-31 2012-07-31
US13/946,344 US8901305B2 (en) 2012-07-31 2013-07-19 Aryl lactam kinase inhibitors
PCT/US2013/051831 WO2014022167A1 (en) 2012-07-31 2013-07-24 Aryl lactam kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2015000980A true MX2015000980A (es) 2015-04-10

Family

ID=50026068

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000980A MX2015000980A (es) 2012-07-31 2013-07-24 Inhibidores de aril lactama cinasa.

Country Status (12)

Country Link
US (1) US8901305B2 (es)
EP (1) EP2880032B1 (es)
JP (1) JP2015528018A (es)
CN (1) CN104507941A (es)
AR (1) AR093758A1 (es)
BR (1) BR112015001890A2 (es)
CA (1) CA2880523A1 (es)
EA (1) EA201590268A1 (es)
ES (1) ES2602965T3 (es)
MX (1) MX2015000980A (es)
TW (1) TW201410676A (es)
WO (1) WO2014022167A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2958924B1 (en) 2013-02-22 2016-12-28 Bristol-Myers Squibb Company 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
US10253027B2 (en) 2013-07-08 2019-04-09 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2937529A1 (en) * 2014-01-29 2015-08-06 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
EA028942B1 (ru) 2014-04-02 2018-01-31 Бристол-Майерс Сквибб Компани Биарильные ингибиторы киназы
EP3292124B1 (en) * 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
WO2017059085A1 (en) * 2015-10-01 2017-04-06 Bristol-Myers Squibb Company Biaryl kinase inhibitors
WO2017059080A1 (en) * 2015-10-01 2017-04-06 Bristol-Myers Squibb Company Biaryl kinase inhibitors
WO2021026349A1 (en) * 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
CN114853664B (zh) * 2022-06-02 2023-09-29 河南大学 一种钯催化条件下合成α,β-不饱和杂环己基酮类化合物的方法
CN116102542A (zh) * 2023-02-15 2023-05-12 如东众意化工有限公司 环丙唑醇精制母液中环丙唑醇的回收方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
CA2400368A1 (en) 1992-12-02 1994-06-09 Allen J. Duplantier Catechol diethers as selective pde iv inhibitors
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
ES2301793T3 (es) 2002-04-05 2008-07-01 Boehringer Ingelheim Pharmaceuticals Inc. Cianamidas utiles como inhibidores reversibles de cisteina proteasas.
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
RU2006133265A (ru) * 2004-02-18 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Гетероциклические модуляторы, селективные в отношении подтипа рецептора гамка
US20050288338A1 (en) 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
WO2007068465A1 (en) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
EP2001886A2 (en) * 2006-03-07 2008-12-17 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
EP2007756B1 (en) 2006-04-07 2015-08-26 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2008022154A2 (en) 2006-08-14 2008-02-21 Wyeth Methods of identifying agents for treating neurological disorders
WO2008079933A2 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
MX2011012015A (es) * 2009-05-15 2012-04-30 Univ Kentucky Res Found Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
US8791257B2 (en) * 2010-03-31 2014-07-29 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
US8969565B2 (en) 2012-03-09 2015-03-03 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use
US8946415B2 (en) 2012-03-09 2015-02-03 Lexicon Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
WO2013134336A2 (en) 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors

Also Published As

Publication number Publication date
CN104507941A (zh) 2015-04-08
AR093758A1 (es) 2015-06-24
TW201410676A (zh) 2014-03-16
CA2880523A1 (en) 2014-02-06
EP2880032A1 (en) 2015-06-10
US8901305B2 (en) 2014-12-02
EA201590268A1 (ru) 2015-05-29
ES2602965T3 (es) 2017-02-23
JP2015528018A (ja) 2015-09-24
US20140038999A1 (en) 2014-02-06
WO2014022167A1 (en) 2014-02-06
EP2880032B1 (en) 2016-10-05
BR112015001890A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
MX2015000980A (es) Inhibidores de aril lactama cinasa.
MX2016012829A (es) Inhibidores de biaril cinasa.
WO2013134336A3 (en) Inhibition of adaptor associated kinase 1 for the treatment of pain
PH12017502141A1 (en) Compounds and their methods of use
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.
MX2012013197A (es) Inhibidores de indazol de cinasa.
HK1220355A1 (zh) Mk2抑制劑和其用途
EA201491647A1 (ru) Основанные на арилэфирах ингибиторы киназ
PH12014502704A1 (en) Compounds and compositions for modulating egfr activity
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
MX2016009352A (es) Inhibidores de quinasa a base de quinolina.
MX336726B (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MX2016009355A (es) Inhibidores de aril lactama cinasa.
PH12013502516A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
PH12016501071B1 (en) Serine/threonine kinase inhibitors
IN2014CN04050A (es)
AU2015292632B2 (en) Aldosterone synthase inhibitors
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
TW201612165A (en) Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound
MA39824A (fr) Composés azole amido-substitués
WO2016164295A3 (en) Fused pyridines as adaptor associated kinase 1 (aak1) inhibitors
WO2013165898A3 (en) Compositions and methods for inhibiting resolvases